High-dose therapy and autologous stem cell transplantation for chemoresistant Hodgkin lymphoma: the Seattle experience. - Wikidata - thesis-toulmin - TriplyDB

High-dose therapy and autologous stem cell transplantation for chemoresistant Hodgkin lymphoma: the Seattle experience.

High-dose therapy and autologous stem cell transplantation for chemoresistant Hodgkin lymphoma: the Seattle experience.

http://www.wikidata.org/entity/Q37238152

about

The role of autologous and allogeneic hematopoietic stem cell transplantation for Hodgkin lymphoma Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation Phase II study of sorafenib in patients with relapsed or refractory lymphoma.Improving the treatment of non-Hodgkin lymphoma with antibody-targeted radionuclides.The Management of Classical Hodgkin's Lymphoma: Past, Present, and Future Autologous hematopoietic stem cell transplantation in classical Hodgkin's lymphoma Predicting treatment outcome in classical Hodgkin lymphoma: genomic advances Double high-dose therapy with dose-intensive cyclophosphamide, etoposide, cisplatin (DICEP) followed by high-dose melphalan and autologous stem cell transplantation for relapsed/refractory Hodgkin lymphoma.Hematopoietic cell transplantation for lymphomas.Autologous hematopoietic cell transplantation: an update for clinicians.Current role of autologous and allogeneic stem cell transplantation for relapsed and refractory hodgkin lymphoma.Primary refractory and early-relapsed Hodgkin's lymphoma: strategies for therapeutic targeting based on the tumour microenvironment.Microenvironment-related biomarkers and novel targets in classical Hodgkin's lymphoma.Improving outcomes after allogeneic hematopoietic cell transplantation for Hodgkin lymphoma in the brentuximab vedotin era Quality of life of long-term survivors with Hodgkin lymphoma after high-dose chemotherapy, autologous stem cell transplantation, and conventional chemotherapy.

P2860

Q26822480-060AD854-BFFE-4A09-A8C4-B4157F28315B Q33400803-10A18608-1A96-43E6-8037-AC4FD0C6CA9C Q33401136-019B90BB-B244-407C-9877-A0F9D76B79EF Q33645793-A3AB0FE2-3A23-4BBD-829F-D8F613A79339 Q35038852-246C4C27-2452-4D5D-AE63-73A68C1C76E6 Q36464310-EB5E5A12-FB32-453D-8C48-2535E52D9F91 Q37872044-5E1D67D6-E6E4-4898-9FCF-4255CD4A17AA Q37934952-DBEFEEDE-9F1D-4BAC-BF3D-9FFC44F1EA06 Q37942817-C425664A-2249-4D12-B111-900E47BADF81 Q38248359-8205016D-90A2-4076-A989-52F909678ED6 Q38368587-F832EFDA-50FB-4974-8CC2-26FB233E4448 Q38466376-6A7C069E-EEDA-4DA1-BA33-77DE30BF4D9C Q38557033-5B185F85-F7AB-4950-9229-98568363271E Q38992200-91290B40-C809-4811-8EE8-9D8C02A1521E Q48786872-4D8D0C60-0865-42E4-B3AB-C78AF26B6CF0

P2860

High-dose therapy and autologous stem cell transplantation for chemoresistant Hodgkin lymphoma: the Seattle experience.

http://www.wikidata.org/entity/Q37238152

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on September 2008

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

High-dose therapy and autologo ...... phoma: the Seattle experience.

@en

High-dose therapy and autologo ...... phoma: the Seattle experience.

@nl

type

label

High-dose therapy and autologo ...... phoma: the Seattle experience.

@en

High-dose therapy and autologo ...... phoma: the Seattle experience.

@nl

prefLabel

High-dose therapy and autologo ...... phoma: the Seattle experience.

@en

High-dose therapy and autologo ...... phoma: the Seattle experience.

@nl

P1433

Q37238152-05C6ECC2-C6A4-416C-8F44-C7A7B650476D

P1476

Q37238152-C3AF9B84-7BAB-458E-81BA-06BD6E30F321

P2093

Q37238152-0BE1DC82-AF91-4C24-82C6-B3250F806F9B

Q37238152-939952CD-8C80-401D-BC3D-705CBF81C49B

Q37238152-AACDE1B8-B8AE-4D7C-AC50-8DA3EF0E665E

Q37238152-B9F043C3-DD95-4BC3-969F-A4162ED3A145

Q37238152-BA386212-BE78-4C58-8CD4-7AA51269417C

Q37238152-E59623CC-A250-42FB-8001-3B81B70A2EFE

Q37238152-F5A5800B-A3F6-4766-B72B-5D35E63DB115

P2860

Q37238152-05F02784-863A-4632-8E5C-200675175129

Q37238152-0B3905D0-1A54-4A6D-871A-267E5113C1FD

Q37238152-11424059-3EB7-41CA-93B6-C19643C734E8

Q37238152-1871473A-3C4E-4C80-BAD4-1ABEF53EB506

Q37238152-1B6A951A-F523-43E6-9C13-2B7B75A6BF39

Q37238152-1DC92F94-BB27-4DED-9980-D68125AD09A6

Q37238152-2ACFCE66-3F5A-4D5B-AA3D-4EAE7EFF1F68

Q37238152-413B724B-A97A-4D6A-B84F-3361D5ADFD70

Q37238152-53D43DD4-A93C-4DE6-A0F9-5F990336F4E0

Q37238152-62EDFA97-4C7B-4D73-9E49-945B69467DE3

P304

Q37238152-6C46EAC0-6CD0-4B15-AF92-9123908E5159

P31

Q37238152-89079FBB-00C5-4C51-A098-EEF0500CA951

P356

Q37238152-C217FB2F-CCE1-492F-9527-8B206A6B38C1

P407

Q37238152-89065C40-79ED-4492-A1BE-C8FD6D9BE0E2

P433

Q37238152-2DAA811B-C8B5-4D70-AD90-23953C492D90

P478

Q37238152-FCAD8A18-FFFA-4B9C-96D9-315C843BF7A4

P50

Q37238152-1BF99C28-ACBA-4251-B7CA-B1B6BBA505B8

Q37238152-72D8B43D-5BDB-4F27-A065-44B778D0765C

P577

Q37238152-254C7099-B0A0-40BB-ABE0-C3E2A3C1D668

P5875

Q37238152-B7E33E50-14A1-4BA9-82DF-0106A2E5BD08

P698

Q37238152-1D5AE51B-2FA7-4344-90C4-94EB3BF25C13

P932

Q37238152-C8080F84-7913-4FD8-972F-D3C4F4F2409B

P356

P1433

P1476

High-dose therapy and autologo ...... phoma: the Seattle experience.

@en

P2093

Ajay K Gopal

http://www.w3.org/2001/XMLSchema#string

John M Pagel

http://www.w3.org/2001/XMLSchema#string

Leona Holmberg

http://www.w3.org/2001/XMLSchema#string

Oliver W Press

http://www.w3.org/2001/XMLSchema#string

Ted A Gooley

http://www.w3.org/2001/XMLSchema#string

Tracee L Metcalfe

http://www.w3.org/2001/XMLSchema#string

William I Bensinger

http://www.w3.org/2001/XMLSchema#string

P2860

Cancer statistics, 2005

Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804.

A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease.

Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial.

Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial.

Favorable outcome of patients with relapsed or refractory Hodgkin's disease treated with high-dose chemotherapy and stem cell rescue at the time of maximal response to conventional salvage therapy (Dex-BEAM).

An update on the management of relapsed and primary refractory Hodgkin's disease.

A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma

Effective therapy for a murine model of human anaplastic large-cell lymphoma with the anti-CD30 monoclonal antibody, HeFi-1, does not require activating Fc receptors

A phase 1 multidose study of SGN-30 immunotherapy in patients with refractory or recurrent CD30+ hematologic malignancies

P304

1344-1350

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/CNCR.23715

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

113

http://www.w3.org/2001/XMLSchema#string

P50

David G. Maloney

Stephen H Petersdorf

P577

2008-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5227800

http://www.w3.org/2001/XMLSchema#string

P698

18623377

http://www.w3.org/2001/XMLSchema#string

P932

2700660

http://www.w3.org/2001/XMLSchema#string